华润双鹤：全资子公司部分药品获得药品注册证书

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiaries have obtained drug registration certificates for three new products, enhancing the company's product line and market competitiveness [1] Group 1: Drug Registration - Beijing Wanhui Double Crane Pharmaceutical Co., Ltd. received a registration certificate for Amlodipine Benazepril Capsules, which are used to treat hypertension [1] - China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. obtained a registration certificate for Tocilizumab Sustained-Release Tablets, aimed at treating rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [1] - Double Crane Pharmaceutical (Hainan) Co., Ltd. secured a registration certificate for Valsartan Fumarate Tablets, which are indicated for gastroesophageal reflux disease [1] Group 2: R&D Investment - The cumulative R&D investment for Amlodipine Benazepril Capsules was 9.5161 million yuan [1] - The cumulative R&D investment for Tocilizumab Sustained-Release Tablets was 11.755 million yuan [1] - The cumulative R&D investment for Valsartan Fumarate Tablets was 7.6947 million yuan [1] Group 3: Market Impact - The acquisition of these registration certificates will further enrich the company's product line [1] - The new products are expected to enhance the company's market competitiveness in the pharmaceutical industry [1]